Quotient Sciences has been recognized as a finalist in two categories of the 2024 Fierce CRO Awards.
The Fierce CRO Awards celebrate exceptional achievements and innovations by Contract Research Organizations (CROs). These awards recognize CROs that have demonstrated outstanding performance, innovation, and leadership in delivering high-quality research and development services.
Entries in the 2024 Fierce CRO Awards were judged on the ability of the applicant to demonstrate innovation, impact, measurable outcomes, sustainability, scalability, ethical and regulatory adherence. This includes:
- The level of creativity and effectiveness in advancing research and development services within the life sciences sector
- Evidence of tangible results and improvements, such as successful trials, enhanced data quality, or improved client satisfaction
- The potential for long-term impact and the ability to apply successful practices on a broader scale
- Commitment to maintaining high ethical standards and complying with relevant regulations
The company was recognized for its submissions to the Excellence in Client Service and Partnership category, highlighting recent work in partnership with companies including YourChoice Therapeutics and its leading YCT-529 candidate. YCT-529 is currently the only hormone-free birth control pill for men that researchers are testing in humans.
In the Innovative Solutions in Drug Development category, the company highlighted the impact of the company's Translational Pharmaceutics platform for integrated drug development to programs with Evecxia Therapeutics on EVX-101 and with Ensysce Biosciences on PF614-MPAR.
Translational Pharmaceutics® integrates real-time cGMP drug product manufacturing (including oral solid dosage forms, such as tablets and capsules), clinical testing, project management, data sciences, and related capabilities needed to fully execute a Phase I clinical trial with healthy volunteers. Combining services and expertise as both a CDMO and CRO into one program makes it easy for clients to complete their programs, while benefitting from a single project manager for the entire process with oversight of a cross-functional project team. Each year, Quotient Sciences are consistently a leading provider of Phase I clinical trials in the UK.
"Giving our customers direct lines of communication to subject matter experts and more integrated way to complete drug programs are two things that consistently set us apart from other CDMOs and CROs." said Thierry Van Nieuwenhove, CEO, Quotient Sciences. "I'm proud of our teams and the wealth of our scientific knowledge that we are able to showcase to the industry."
Winners will be announced in the Fierce CRO Report in December.